000 -LEADER |
fixed length control field |
03749nam a22004335i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-540-72146-8 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20161121230807.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
100301s2008 gw | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783540721468 |
-- |
978-3-540-72146-8 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/978-3-540-72146-8 |
Source of number or code |
doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
QR355-502 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MMFM |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED052000 |
Source |
bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
616.9101 |
Edition number |
23 |
245 10 - TITLE STATEMENT |
Title |
Human Antibody Therapeutics for Viral Disease |
Medium |
[electronic resource] / |
Statement of responsibility, etc. |
edited by Scott K. Dessain. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Berlin, Heidelberg : |
Name of producer, publisher, distributor, manufacturer |
Springer Berlin Heidelberg, |
Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
XII, 190 p. 18 illus., 7 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
490 1# - SERIES STATEMENT |
Series statement |
Current Topics in Microbiology and Immunology, |
International Standard Serial Number |
0070-217X ; |
Volume/sequential designation |
317 |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Therapeutic Control of Hepatitis C Virus: The Role of Neutralizing Monoclonal Antibodies -- Antibodies for HIV Treatment and Prevention: Window of Opportunity? -- Human Monoclonal Antibody and Vaccine Approaches to Prevent Human Rabies -- Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab -- The Molecular Basis of Antibody Protection Against West Nile Virus -- Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
The articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conceptual model for the clinical use of HCV-specific antibodies. Huber et al. summarize the initial clinical experiences with antibody therapeutics for Human Immunodeficiency Virus that can be targeted to either the HIV virion or to host cell proteins. A discussion of the breadth immune strategies that is required to control human rabies is provided by Nagarajan et al., with a particular focus on India and other countries in which rabies is endemic. The development of pavilizumab for RSV prophylaxis is reviewed in Wu et al., in addition to results of antibody optimization studies that provide surprising insights and have broad general implications for anti-viral antibody engineering. Melhop and Diamond explicate the biology of West Nile Virus as a general model for flaviviruses, while using their cloned antibodies as a springboard to consider the mechanisms of WNV neutralization. The volume concludes with a description of methods to clone human antibodies in their native configurations, which access a class of antibodies that differ from those obtained by recombinant DNA or transgenic mouse methods. The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Medicine. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Virology. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Biomedicine. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Virology. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Dessain, Scott K. |
Relator term |
editor. |
710 2# - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY |
Title |
Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9783540721444 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Current Topics in Microbiology and Immunology, |
International Standard Serial Number |
0070-217X ; |
Volume/sequential designation |
317 |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-3-540-72146-8 |
912 ## - |
-- |
ZDB-2-SBL |